Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Bind Biosciences (Cambridge, MA) a clinical-stage biopharmaceutical company focused on new class of highly selective targeted chemotherapeutic nano-therapeutics for solid tumors, closed a $25.5M Series D financing. Participants include Rusnano.

Bind Biosciences (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on differential medicinal nanoengineered delivery of targeted therapeutics and controlled drug exposure to diseased tissue for various cancers, closed an $11M Series C financing. Participants have included DHK Investments, ARCH Venture Partners, Flagship Ventures, NanoDimension and Polaris Venture Partners.

EyeGate Pharma (Wlatham, MA) a clinical-stage company focused on a non-invasive iontophoresis drug delivery system for ocular therapeutics, closed a $22.6M Series D financing. Participants include Natixis Private Equity, Emerging Capital, Ventech, Innoven Partners and Medicis Capital.

Terapio (Austin, TX) a preclinical-stage biopharmaceutical company focused on radiodermatitis, closed a $5M Series A financing. Participants have included Santé Ventures and Texas Emerging Technology Fund. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Traversa Therapeutics (La Jolla, CA) a preclinical-stage biopharmaceutical company developing RNAi delivery technologies, closed a $5M Series B financing. Participants include Morningside, Mesa Verde Venture Partners and Tech Coast Angels.

  

to top of page...